These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32527579)

  • 21. Soft tissue infections and the diabetic foot.
    Smith AJ; Daniels T; Bohnen JM
    Am J Surg; 1996 Dec; 172(6A):7S-12S. PubMed ID: 9003684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report.
    Goldberg E; Bishara J; Lev S; Singer P; Cohen J
    Transpl Infect Dis; 2012 Jun; 14(3):296-9. PubMed ID: 22176504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
    Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
    Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Klebsiella pneumoniae O antigen contributes to bacteremia and lethality during murine pneumonia.
    Shankar-Sinha S; Valencia GA; Janes BK; Rosenberg JK; Whitfield C; Bender RA; Standiford TJ; Younger JG
    Infect Immun; 2004 Mar; 72(3):1423-30. PubMed ID: 14977947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Factors for Carbapenem-resistant
    Wang Z; Qin RR; Huang L; Sun LY
    Chin Med J (Engl); 2018 Jan; 131(1):56-62. PubMed ID: 29271381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.
    Patel G; Huprikar S; Factor SH; Jenkins SG; Calfee DP
    Infect Control Hosp Epidemiol; 2008 Dec; 29(12):1099-106. PubMed ID: 18973455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
    Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
    Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
    Shields RK; Nguyen MH; Chen L; Press EG; Potoski BA; Marini RV; Doi Y; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infections caused by carbapenem-resistant Klebsiella pneumoniae with hypermucoviscous phenotype: A case report and literature review.
    Arena F; Henrici De Angelis L; D'Andrea MM; Cannatelli A; Fossati L; Di Pilato V; Giani T; Cavallo R; Rossolini GM
    Virulence; 2017 Nov; 8(8):1900-1908. PubMed ID: 28276993
    [No Abstract]   [Full Text] [Related]  

  • 31. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections.
    Oliva A; D'Abramo A; D'Agostino C; Iannetta M; Mascellino MT; Gallinelli C; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2014 Jun; 69(6):1718-20. PubMed ID: 24521856
    [No Abstract]   [Full Text] [Related]  

  • 32. Determining the resistance of carbapenem-resistant Klebsiella pneumoniae to common disinfectants and elucidating the underlying resistance mechanisms.
    Guo W; Shan K; Xu B; Li J
    Pathog Glob Health; 2015 Jun; 109(4):184-92. PubMed ID: 26184804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
    Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
    Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
    J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenic spectrum of blood stream infections and resistance pattern in Gram-negative bacteria from Aljouf region of Saudi Arabia.
    Bandy A; Almaeen AH
    PLoS One; 2020; 15(6):e0233704. PubMed ID: 32516308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid peroxidation in Gram-negative bacteremia modulates the risk for septic shock and infections by resistant Klebsiella pneumoniae.
    Christodoulou S; Kyriazopoulou E; Chrysanthakopoulou M; Karlis G; Karampela I; Gkizeli K; Veliki N; Safarika A; Giamarellos-Bourboulis EJ; Adamis G;
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2171-2177. PubMed ID: 28639164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nontoxic Three-Part Combination Local Wound Therapy to Eradicate Carbapenem-Resistant Klebsiella pneumoniae.
    Kim N; Murphy M; Choudry U
    Adv Skin Wound Care; 2018 Nov; 31(11):521-523. PubMed ID: 30335644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.
    Falagas ME; Tansarli GS; Karageorgopoulos DE; Vardakas KZ
    Emerg Infect Dis; 2014 Jul; 20(7):1170-5. PubMed ID: 24959688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.